Table 2: Grading of Recommendations Assessment, Development
and Evaluation (GRADE).
|
|
|
|
|
|
|
|
|
Summary of Results |
|
|
||||
|
|
Quality Assessment |
# of patients |
Effect |
Quality |
Importance |
|||||||||
|
# of studies |
Design |
Risk of bias |
Inconsistency |
Indirectness |
Imprecision |
|
Other considerations |
Vitamin D groups |
Placebo groups |
Relative (95% CI) |
Absolute |
|
|
|
|
|
Serological levels of
vitamin D3 |
|||||||||||||
|
4 |
RCTs |
No serious risk of bias |
No serious inconsistency |
No serious indirectness |
No serious imprecision |
|
None |
414 |
402 |
- |
-0.75 [-0.89,-0.60] |
⊕⊕⊕⊕ HIGH |
IMPORTANT |
|
|
|
Serological calcium
levels |
|||||||||||||
|
2 |
RCTs |
No serious risk of bias |
No serious inconsistency |
No serious indirectness |
No serious imprecision |
|
None |
66 |
66 |
- |
2.13 [1.47, 2.80] |
⊕⊕⊕⊕ HIGH |
CRITICAL |
|
|
|
WOMAC pain |
|||||||||||||
|
3 |
RCTs |
No serious risk of bias |
No serious inconsistency |
No serious indirectness |
No serious imprecision |
|
None |
334 |
328 |
- |
1.08 [0.90,1.25] |
⊕⊕⊕⊕ HIGH |
CRITICAL |
|
|
|
WOMAC function |
|||||||||||||
|
3 |
RCTs |
No serious risk of bias |
No serious inconsistency |
No serious indirectness |
No serious imprecision |
|
None |
334 |
328 |
- |
1.10 [0.92,1.27] |
⊕⊕⊕⊕ HIGH |
CRITICAL |
|
|
|
WOMAC stiffness |
|||||||||||||
|
2 |
RCTs |
No serious risk of bias |
No serious inconsistency |
No serious indirectness |
No serious imprecision |
|
None |
261 |
255 |
- |
0.72 [0.54,0.90] |
⊕⊕⊕⊕ HIGH |
CRITICAL |
|
|
|
Changes in tibial
cartilage volume |
|||||||||||||
|
2 |
RCTs |
No serious risk of bias |
No serious inconsistency |
No serious indirectness |
No serious imprecision |
|
None |
282 |
277 |
- |
0.62 [0.44,0.80] |
⊕⊕⊕⊕ HIGH |
CRITICAL |
|
|
|
Adverse events |
|||||||||||||
|
3 |
RCTs |
No serious risk of bias |
No serious inconsistency |
No serious indirectness |
No serious imprecision |
|
None |
162/519 (31.2%) |
147/514 (28.6%) |
RR=1.06 |
- |
⊕⊕⊕⊕ HIGH |
IMPORTANT |
|